mitobronitol has been researched along with Leukemia* in 7 studies
7 other study(ies) available for mitobronitol and Leukemia
Article | Year |
---|---|
Course and transformation of polycythaemia vera in relation to therapy.
The fate of the polycythaemic patient depends on the treatment employed which may determine the nature of the transformation commonly occurring late in the course of the disease. Treatment is, on the other hand, aimed at prevention of the most frequent complications, that is of thromboembolic processes. In the last 30 years the authors treated a total of 118 PV patients, of whom 60 have died. Initially 32P treatment was applied, which was modified later, because of acute leukaemia that had occurred in 9% of the treated cases, to a single 5 mC 32P+Myelobromol (DBM) treatment. Still later only DBM was administered in the form of stosstherapy (2500 mg per day over a period of 4 days). In the latter two groups, acute leukaemia occurred as few as two cases. The course of untreated polycythaemia vera is characterized by transformation into another myeloproliferative disease. This phenomenon occurs in 50% of the cases on drastic treatment and in patients treated with 32P. Of the patients who were alive when the report was finished 35% had been free of complications, while 5.2% were suffering from chronic granulocytic leukaemia (CGL), 34.5% from sclerotic osteo-myelofibrosis (OMF-SC) and 3.4% from chronic megakaryocytic granulocytiv leukaemia (CMGL). Of the 60 patients having died, 15% had suffered from other complications being predominantly of vascular nature. 11.8% of them died of AML, 10% of CGL, 26.7% of OMF-SC and 26.7% of CMGL. The terminal stage was characterized, in the majority of cases, by blastic crisis. Based on their own results and literary data authors recommend DBM treatment besides the indispensable phlebotomy. Topics: Adult; Aged; Aged, 80 and over; Chlorambucil; Female; Humans; Leukemia; Leukemia, Radiation-Induced; Male; Middle Aged; Mitobronitol; Phosphorus Radioisotopes; Polycythemia Vera; Primary Myelofibrosis | 1988 |
Decreasing risk of leukaemia during prolonged follow-up after mitobronitol therapy for polycythaemia vera.
Topics: Aged; Follow-Up Studies; Humans; Leukemia; Mannitol; Mitobronitol; Polycythemia Vera; Risk | 1987 |
[Polycythemia vera associated with marked pancytopenia in transition from the polycythemic stage to leukemia--a case report].
Topics: Humans; Leukemia; Middle Aged; Mitobronitol; Pancytopenia; Polycythemia Vera | 1987 |
Mitobronitol: an alkylating agent that does not induce extra leukemia cases if applied as pulse therapy for polycythemia vera.
Topics: Alkylating Agents; Drug Administration Schedule; Humans; Leukemia; Mannitol; Mitobronitol; Polycythemia Vera | 1985 |
[Leukemia planning of chemotherapy].
Topics: Aged; Busulfan; Drug Administration Schedule; Drug Therapy, Combination; Humans; Leukemia; Leukemia, Myeloid; Mitobronitol; Zinostatin | 1975 |
[TRIAL TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH DIBROMOMANNITOL].
Topics: Amenorrhea; Antineoplastic Agents; Female; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukocytosis; Mitobronitol | 1964 |
[Trial treatment of neoplastic diseases by 1,6-dibromomannitol].
Topics: Antineoplastic Agents; Humans; Leukemia; Leukemia, Myeloid; Mannitol; Mitobronitol; Neoplasms | 1963 |